Provectus Pharmaceuticals, Inc.

(Public, OTC:PVCT)

StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including one nearly entering Phase II for Breast Cancer, one of the largest target markets worldwide and seeking “compassionate use” in Australia and USA, look for Provectus to make a splash within the next couple of months.

They are developing and testing one of the most exciting anti- cancer compounds. It has been demonstrating significant effectiveness against Melanoma in Phase 2 clinical trials and it offers promising treatment for breast, liver and other solid tumor based metastatic cancers. The compound developed by Provectus, known as PV-10, is a

...

Genta Incorporated (GNTA) is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer. The company's leading candidate, Genasense, got a non-approvable letter from the FDA in December 2006. As expected, in early December 2008, the FDA issued a complete response letter indicating that the company needs to conduct an additional clinical study for Genasense in order to receive approval for CLL. Meanwhile, positive results from the AGENDA trial will support the worldwide filing of Genasense as a treatment for melanoma. However, results from the phase III trial are not expected before mid-2009. Therefore, we rate the shares Hold with a revised target price of $0.25.Maharathi Basu contributed to this report.Read the full analyst report on GNTA "GNTA" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

Genta Incorporated (GNTA) is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer. The company's leading candidate, Genasense, got a 'non-approvable' notice from the FDA on December 15, 2006. The company filed an appeal with the FDA in April 2007 and got a positive response from the FDA in March 2008.

Additionally, positive results from the AGENDA trial will support the worldwide filing of Genasense as a treatment for melanoma. However, results from the phase III trial are not expected before mid-2009. Therefore, we rate the shares Hold with a target price of $0.70 on a market cap of $26 million.

In April 2008, the company reduced its workforce by approximately 30% in order to conserve cash. Genta also announced that it would seek a buyer for its sole marketed product, Ganite. We do not see the company attaining profitability in the near future. We believe

...

We maintain a Hold rating on Genta Incorporated (GNTA), a biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer.

Unfortunately, the company has entered into a survival mode due to the shortage of cash. With the non-approval of Genasense for chronic lymphocytic leukemia by FDA, the future of Genasense remains uncertain. In July 2007, the EMEA indicated that approval of Genasense in melanoma will require the conduct of another clinical study. Genta believes that the AGENDA trial will be able to address the EMEA’s requirement adequately.

Positive data from this trial will enable the company for the worldwide filing of Genasense as a treatment for melanoma. However, we do not expect to see data from the trial before end-2008. The company had cash and marketable securities of only $16.3 million at June 30, 2008. It raised $3.1 million through the issuance of 6 million shares

...